WO2010089671A3 - Contiguous overlapping peptides for treatment of birch pollen allergy - Google Patents

Contiguous overlapping peptides for treatment of birch pollen allergy Download PDF

Info

Publication number
WO2010089671A3
WO2010089671A3 PCT/IB2010/000393 IB2010000393W WO2010089671A3 WO 2010089671 A3 WO2010089671 A3 WO 2010089671A3 IB 2010000393 W IB2010000393 W IB 2010000393W WO 2010089671 A3 WO2010089671 A3 WO 2010089671A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
birch pollen
overlapping peptides
contiguous overlapping
pollen allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/000393
Other languages
French (fr)
Other versions
WO2010089671A2 (en
Inventor
Christophe Reymond
Francois Spertini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anergis SA
Original Assignee
Anergis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42358661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010089671(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to HRP20160426TT priority Critical patent/HRP20160426T1/en
Priority to CA2750705A priority patent/CA2750705C/en
Priority to DK10707962.6T priority patent/DK2393511T4/en
Priority to PL10707962T priority patent/PL2393511T5/en
Priority to EP10707962.6A priority patent/EP2393511B2/en
Application filed by Anergis SA filed Critical Anergis SA
Priority to JP2011548808A priority patent/JP5566404B2/en
Priority to SI201031170A priority patent/SI2393511T1/en
Priority to ES10707962.6T priority patent/ES2569619T3/en
Priority to AU2010212039A priority patent/AU2010212039C1/en
Publication of WO2010089671A2 publication Critical patent/WO2010089671A2/en
Publication of WO2010089671A3 publication Critical patent/WO2010089671A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of birch pollen Bet v 1. Such peptides while providing all potential T cell epitopes are devoid of the 3D structure of the original allergen, therefore reducing their ability to bind IgE.
PCT/IB2010/000393 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy Ceased WO2010089671A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2010212039A AU2010212039C1 (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy
SI201031170A SI2393511T1 (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy
DK10707962.6T DK2393511T4 (en) 2009-02-09 2010-02-09 ADJUSTING, OVERLAPPING PEPTIDES FOR TREATMENT OF BIRTH POLLENGE ALLERGY
PL10707962T PL2393511T5 (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy
EP10707962.6A EP2393511B2 (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy
HRP20160426TT HRP20160426T1 (en) 2009-02-09 2010-02-09 NEIGHBORHOOD POLLUTION PEPTIDES FOR TREATMENT OF ALLIANCE OF BIRD POLLAR
JP2011548808A JP5566404B2 (en) 2009-02-09 2010-02-09 Sequential overlapping peptides for the treatment of birch pollen allergy
CA2750705A CA2750705C (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy
ES10707962.6T ES2569619T3 (en) 2009-02-09 2010-02-09 Overlapping contiguous peptides for the treatment of birch pollen allergy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15104509P 2009-02-09 2009-02-09
US61/151,045 2009-02-09

Publications (2)

Publication Number Publication Date
WO2010089671A2 WO2010089671A2 (en) 2010-08-12
WO2010089671A3 true WO2010089671A3 (en) 2010-10-14

Family

ID=42358661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/000393 Ceased WO2010089671A2 (en) 2009-02-09 2010-02-09 Contiguous overlapping peptides for treatment of birch pollen allergy

Country Status (12)

Country Link
US (2) US8343503B2 (en)
EP (1) EP2393511B2 (en)
JP (2) JP5566404B2 (en)
AU (1) AU2010212039C1 (en)
CA (1) CA2750705C (en)
DK (1) DK2393511T4 (en)
ES (1) ES2569619T3 (en)
HR (1) HRP20160426T1 (en)
HU (1) HUE027491T2 (en)
PL (1) PL2393511T5 (en)
SI (1) SI2393511T1 (en)
WO (1) WO2010089671A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20115374A0 (en) 2011-04-18 2011-04-18 Teknologian Tutkimuskeskus Vtt Oy New hypoallergens
CA2839832C (en) * 2011-06-27 2018-08-28 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
EP2746396A1 (en) * 2012-12-20 2014-06-25 PLS-Design GmbH Selective local inhibition of TNFR1-mediated functions at the site of antigen/allergen presentation
CA2914037A1 (en) * 2013-06-06 2014-12-11 Anergis S.A. Contiguous overlapping peptides for treatment of house dust mites allergy
WO2020121062A1 (en) * 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1219299B2 (en) 2000-12-28 2010-11-10 Biomay Ag Allergy vaccines and their preparation
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
CA2678170A1 (en) 2007-02-14 2008-08-21 Universitaet Salzburg Hypoallergenic proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARNIER VON C ET AL: "Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY - V C H VERLAG GMBH & CO. KGAA, DE LNKD- DOI:10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R, vol. 30, no. 6, 1 June 2000 (2000-06-01), pages 1638 - 1645, XP002297947, ISSN: 0014-2980 *
NIEDERBERGER V ET AL: "Vaccination with genetically engineered allergens prevents progression of allergic disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.0404735101, vol. 101, no. SUPPL 2, 5 October 2004 (2004-10-05), pages 14677 - 14682, XP002373813, ISSN: 0027-8424 *
PUROHIT A ET AL: "Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 38, no. 9, September 2008 (2008-09-01), pages 1514 - 1525, XP002595735, ISSN: 0954-7894 *
VRTALA S ET AL: "Conversion of the major birch pollen allergen, bet v 1, into two nonanaphylactic T cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US LNKD- DOI:10.1172/JCI119330, vol. 99, no. 7, 1 January 1997 (1997-01-01), pages 1673 - 1681, XP002221492, ISSN: 0021-9738 *
VRTALA S ET AL: "GENETIC ENGINEERING OF RECOMBINANT HYPOALLERGENIC OLIGOMERS OF THE MAJOR BIRCH POLLEN ALLERGEN, BET V 1: CANDIDATES FOR SPECIFIC IMMUNOTHERAPY", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, KARGER AG, CH LNKD- DOI:10.1159/000024075, vol. 118, no. 2-04, 1 February 1999 (1999-02-01), pages 218/219, XP008027526, ISSN: 1018-2438 *

Also Published As

Publication number Publication date
PL2393511T5 (en) 2020-08-10
CA2750705A1 (en) 2010-08-12
SI2393511T1 (en) 2016-10-28
AU2010212039C1 (en) 2015-03-05
WO2010089671A2 (en) 2010-08-12
EP2393511B1 (en) 2016-04-06
DK2393511T3 (en) 2016-05-09
JP2012517418A (en) 2012-08-02
PL2393511T3 (en) 2016-11-30
US8343503B2 (en) 2013-01-01
ES2569619T3 (en) 2016-05-11
AU2010212039A1 (en) 2011-07-28
EP2393511B2 (en) 2020-03-25
HUE027491T2 (en) 2016-10-28
EP2393511A2 (en) 2011-12-14
US20100203070A1 (en) 2010-08-12
JP5566404B2 (en) 2014-08-06
AU2010212039B2 (en) 2014-09-18
DK2393511T4 (en) 2020-04-27
HRP20160426T1 (en) 2016-07-29
JP2014037438A (en) 2014-02-27
US20130156799A1 (en) 2013-06-20
CA2750705C (en) 2015-12-29

Similar Documents

Publication Publication Date Title
WO2011094259A3 (en) Cd127 binding proteins
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX336682B (en) Antibodies against human csf-1r and uses thereof.
EP4338754A3 (en) Antigen binding proteins
EP3792278A3 (en) Human anti-tau antibodies
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
MY156286A (en) Human il-23 antigen binding proteins
EP3539988A3 (en) Monoclonal antibodies against her2
MX345092B (en) Human anti-tau antibodies.
WO2015028969A3 (en) Transduction buffer
WO2011110642A3 (en) Monoclonal antibodies against c-met
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2012149365A3 (en) Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies
HK1210192A1 (en) Anti-siglec-15 antibodies
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2014195803A3 (en) Contiguous overlapping peptides for treatment of house dust mites allergy
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2011112566A3 (en) Basigin binding proteins
WO2010089671A3 (en) Contiguous overlapping peptides for treatment of birch pollen allergy
WO2012041867A3 (en) Combined antigen and dna vaccine for preventing and treating autoimmune diseases
EP2928492A4 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
WO2013001362A3 (en) Contiguous overlapping peptides for treatment of ragweed pollen allergy
EP2749570A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707962

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010212039

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011548808

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2750705

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010212039

Country of ref document: AU

Date of ref document: 20100209

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010707962

Country of ref document: EP